Chronic kidney disease (CKD) is diagnosed when kidney function remains below normal for at least three consecutive months, or when structural kidney damage is confirmed through imaging or biopsy. It is not a single condition but a progressive decline in renal function affecting millions globally.
CKD develops slowly over time, often without noticeable symptoms until significant damage has occurred. The kidneys filter waste, regulate electrolytes, balance fluids, and produce hormones essential for red blood cell production and bone health. When their filtering capacity drops below 60 mL/min/1.73 m² for three months or longer, it meets the clinical threshold for CKD.
The National Kidney Foundation defines CKD using two criteria: (1) evidence of kidney damage (such as protein in urine or abnormal imaging), and (2) a glomerular filtration rate (eGFR) below 60 mL/min/1.73 m². Both must persist for at least three months to confirm chronicity. A single low eGFR does not qualify-it must be sustained.
The estimated glomerular filtration rate (eGFR) measures how well the kidneys filter waste from the blood. It's calculated using serum creatinine levels, age, sex, and race. An eGFR below 60 indicates impaired kidney function. Values below 15 signal end-stage renal disease (ESRD), requiring dialysis or transplant.
Albuminuria-the presence of excess albumin in the urine-is another key marker. Urine tests detect albumin-to-creatinine ratio (UACR). A UACR above 30 mg/g indicates kidney damage. Combining eGFR and UACR allows clinicians to stage CKD accurately and assess risk for progression.
For example, a 65-year-old man with diabetes and a consistent eGFR of 45 mL/min/1.73 m² over six months, along with a UACR of 120 mg/g, would be classified as having Stage 3b CKD with moderate albuminuria. This combination predicts higher risk of cardiovascular events and faster decline in kidney function.
CKD is divided into five stages based on eGFR values. Stage 1 (eGFR ≥90) shows normal function but signs of kidney damage. Stage 5 (eGFR <15) is ESRD, requiring renal replacement therapy.
| Stage | eGFR (mL/min/1.73 m²) | Kidney Function | Common Causes |
|---|---|---|---|
| 1 | ≥90 | Normal or high | Diabetes, hypertension, genetic disorders |
| 2 | 60-89 | Mild decrease | Early diabetic nephropathy, aging |
| 3a | 45-59 | Moderate decrease | Long-standing hypertension, obesity |
| 3b | 30-44 | Moderate to severe decrease | Advanced diabetes, autoimmune disease |
| 4 | 15-29 | Severe decrease | Chronic pyelonephritis, obstructive uropathy |
| 5 | <15 | End-stage renal disease | Irreversible failure, advanced fibrosis |
Staging combines eGFR with albuminuria level (A1-A3) to determine prognosis and treatment intensity. For instance, a patient with Stage 3b CKD and A3 albuminuria has a 30% higher risk of progressing to ESRD within five years compared to someone with A1.
CKD is not synonymous with acute kidney injury (AKI). AKI occurs suddenly-over hours or days-and may resolve completely. CKD is irreversible and progresses over months or years. Confusing the two leads to mismanagement; AKI requires urgent intervention, while CKD focuses on slowing decline.
Another frequent error is assuming that symptoms define CKD. Fatigue, swelling, nausea, and itching appear late. Most patients in early stages report no symptoms. Relying on symptoms delays diagnosis. A 2023 study in the Journal of the American Society of Nephrology found that 78% of people with Stage 3 CKD had no reported symptoms at baseline.
Some assume that kidney stones or urinary tract infections equate to CKD. While recurrent UTIs can contribute to scarring, they don't automatically cause chronic damage. Only persistent impairment in filtration or structural changes meet diagnostic criteria.
A 58-year-old woman with type 2 diabetes presents with fatigue and mild ankle swelling. Labs show serum creatinine of 1.8 mg/dL, eGFR of 42 mL/min/1.73 m², and UACR of 210 mg/g. Repeat testing confirms these values over four months. She has no history of acute illness or medication-induced injury.
Her diagnosis is Stage 3b CKD with moderate albuminuria. She was unaware of her condition until routine screening. Without early detection, she would have progressed undetected. Her care plan includes blood pressure control (target <130/80 mmHg), SGLT2 inhibitor therapy, dietary sodium restriction, and regular monitoring of eGFR and UACR.
This case illustrates that CKD is often asymptomatic and relies on lab markers. Routine screening in high-risk groups-diabetics, hypertensives, older adults-is critical. The Centers for Disease Control and Prevention recommends annual eGFR and urine albumin testing for adults over 65 with diabetes or hypertension.
Duration is the defining feature of chronic kidney disease. A single low eGFR value-say, 50-does not equal CKD. If it returns to normal on follow-up, the condition is not chronic. True CKD requires persistence beyond three months.
This distinction prevents overdiagnosis. A 40-year-old athlete with a temporary drop in eGFR due to dehydration would not be labeled CKD. But if the value stays below 60 for three months despite hydration and recovery, then CKD is confirmed.
Understanding this timeline is important. It separates transient stress on the kidneys from lasting damage. The American Society of Nephrology emphasizes that "chronicity" is not about severity but duration. A patient with Stage 1 CKD can still have normal kidney function but ongoing damage.
Chronic kidney disease is not a single event but a measurable, persistent decline in kidney function. Diagnosis hinges on sustained eGFR below 60 and/or evidence of kidney damage. Early detection through lab testing-not symptoms-remains the most effective way to manage this condition.